Business Context and Reporting Period
This Form 8-K was filed by Tempest Therapeutics, Inc. (formerly OvaScience, Inc.) on September 21, 2021. The report documents a corporate governance action taken by the Board of Directors to amend and restate the Company's Bylaws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate bylaws and does not contain financial statements or performance metrics.
Material Changes
- Corporate Name Change: The Company's name on the cover of its Amended and Restated Bylaws was officially changed from "OvaScience, Inc." to "Tempest Therapeutics, Inc."
- Effective Date: The amendment and restatement of the Bylaws became effective on September 21, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural update of the Company's Bylaws.
Investor Verification Checklist
- Confirm the legal name change from OvaScience, Inc. to Tempest Therapeutics, Inc. is reflected in all subsequent filings and trading records.
- Review the attached Exhibit 3.1 (Amended and Restated Bylaws) for any other substantive changes to corporate governance beyond the name update.
- Verify the ticker symbol "TPST" on The Nasdaq Capital Market remains active under the new corporate name.